Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals by Year
Crinetics Pharmaceuticals — Cash and cash equivalents ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals: $102M in FY2025, down 61.6% from a year earlier.
Latest, FY2025
102
Period ended Dec 31, 2025
Change on a year earlier
-61.6%
265 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Cash and cash equivalents ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 102 | -61.6% | SEC Filing ↗ |
| FY2024 | Dec 31, 2024 | 265 | +381.9% | SEC Filing ↗ |
| FY2023 | Dec 31, 2023 | 54.9 | +68.0% | SEC Filing ↗ |
| FY2022 | Dec 31, 2022 | 32.7 | -83.7% | SEC Filing ↗ |
| FY2021 | Dec 31, 2021 | 201 | +115.6% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 93.1 | +130.8% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 40.3 | -10.3% | SEC Filing ↗ |
| FY2018 | Dec 31, 2018 | 45.0 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-cash
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.